The Utility of Cabazitaxel

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.

Clinical Pearls

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.

  • Cabazitaxel was approved several years ago for patients with prostate cancer who progress on docetaxel.
  • Chemotherapy has a clear benefit in treating prostate cancer.
  • The CHAARTED study will likely change the way cabazitaxel is used in practice.